Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.37 Bil Enterprise Value: 13.42 Bil PE Ratio: 71.45 PB Ratio: 2.86 GF Score: 62/100

Biomarin Pharmaceutical Inc at SVB Leerink Global Healthcare (Virtual) Transcript

Feb 18, 2022 / 06:00PM GMT
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - Senior MD of Rare Diseases & Senior Research Analyst

Everyone, welcome to this fireside chat with BioMarin Pharmaceuticals. I'm Joe Schwartz at SVB Securities. It's my pleasure to be joined by Hank Fuchs, President of Worldwide R&D. How are you doing, Hank?

Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Good to see you, Joe. Nice to be here.

Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - Senior MD of Rare Diseases & Senior Research Analyst

So maybe we can start by having you give us a quick overview of the key [initiatives] the company has for this year and the major catalysts that investors should look forward to for your stock.

Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Great. Thanks, Joe. It's a pleasure to be here today to talk to you. 2022 is going to be our most productive

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot